Literature DB >> 17360078

Dose-response studies for the elicitation of CD8 T cells by a DNA vaccine, used alone or as the prime for a modified vaccinia Ankara boost.

Jinyan Liu1, Michael Hellerstein, Michael McDonnel, Rama Rao Amara, Linda S Wyatt, Bernard Moss, Harriet L Robinson.   

Abstract

Here, we conduct dose-response studies in mice for the elicitation of CD8 T cells by a DNA vaccine that expresses HIV Gag. For DNA doses ranging from 1 to 100 microg, the studies revealed greater than 10-fold increases in anti-Gag CD8 T cells following a DNA prime or a DNA prime and a constant modified vaccinia Ankara (MVA) boost. These results are in contrast to dose-response studies for MVA vectors expressing Gag, where only 2-3-fold increases in anti-Gag CD8 T cells were elicited by 100-fold increases in dose.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17360078     DOI: 10.1016/j.vaccine.2006.05.081

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

1.  Comparative studies on in vitro expression and in vivo immunogenicity of supercoiled and open circular forms of plasmid DNA vaccines.

Authors:  Vinod Bhaskara Pillai; Michael Hellerstein; Tianwei Yu; Rama Rao Amara; Harriet L Robinson
Journal:  Vaccine       Date:  2007-10-30       Impact factor: 3.641

2.  Characterization of T-cell responses in macaques immunized with a single dose of HIV DNA vaccine.

Authors:  Géraldine Arrode-Brusés; Darlene Sheffer; Ramakrishna Hegde; Sukbir Dhillon; Zhengian Liu; François Villinger; Opendra Narayan; Yahia Chebloune
Journal:  J Virol       Date:  2009-11-18       Impact factor: 5.103

3.  Oral Immunization with a Recombinant Lactococcus lactis-Expressing HIV-1 Antigen on Group A Streptococcus Pilus Induces Strong Mucosal Immunity in the Gut.

Authors:  Venkateswarlu Chamcha; Andrew Jones; Bernard R Quigley; June R Scott; Rama Rao Amara
Journal:  J Immunol       Date:  2015-10-19       Impact factor: 5.422

Review 4.  Immunogenicity and efficacy of DNA/MVA HIV vaccines in rhesus macaque models.

Authors:  Lynette Siv Chea; Rama Rao Amara
Journal:  Expert Rev Vaccines       Date:  2017-09-04       Impact factor: 5.217

5.  Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells.

Authors:  Thomas J Scriba; Michele Tameris; Nazma Mansoor; Erica Smit; Linda van der Merwe; Fatima Isaacs; Alana Keyser; Sizulu Moyo; Nathaniel Brittain; Alison Lawrie; Sebastian Gelderbloem; Ashley Veldsman; Mark Hatherill; Anthony Hawkridge; Adrian V S Hill; Gregory D Hussey; Hassan Mahomed; Helen McShane; Willem A Hanekom
Journal:  Eur J Immunol       Date:  2010-01       Impact factor: 5.532

6.  Correlation of immunogenicities and in vitro expression levels of recombinant modified vaccinia virus Ankara HIV vaccines.

Authors:  Linda S Wyatt; Patricia L Earl; Jennifer Vogt; Leigh Anne Eller; Dev Chandran; Jinyan Liu; Harriet L Robinson; Bernard Moss
Journal:  Vaccine       Date:  2007-12-03       Impact factor: 3.641

7.  Glycosylation patterns of HIV-1 gp120 depend on the type of expressing cells and affect antibody recognition.

Authors:  Milan Raska; Kazuo Takahashi; Lydie Czernekova; Katerina Zachova; Stacy Hall; Zina Moldoveanu; Matt C Elliott; Landon Wilson; Rhubell Brown; Dagmar Jancova; Stephen Barnes; Jana Vrbkova; Milan Tomana; Phillip D Smith; Jiri Mestecky; Matthew B Renfrow; Jan Novak
Journal:  J Biol Chem       Date:  2010-05-03       Impact factor: 5.157

8.  Insertion of vaccinia virus C7L host range gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens.

Authors:  José Luis Nájera; Carmen Elena Gómez; Juan García-Arriaza; Carlos Oscar Sorzano; Mariano Esteban
Journal:  PLoS One       Date:  2010-06-30       Impact factor: 3.240

9.  Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials.

Authors:  Scott A Brown; Sherri L Surman; Robert Sealy; Bart G Jones; Karen S Slobod; Kristen Branum; Timothy D Lockey; Nanna Howlett; Pamela Freiden; Patricia Flynn; Julia L Hurwitz
Journal:  Viruses       Date:  2010-02-01       Impact factor: 5.048

10.  Targeting 4-1BB (CD137) to enhance CD8 T cell responses with poxviruses and viral antigens.

Authors:  Yuan Zhao; Vikas Tahiliani; Shahram Salek-Ardakani; Michael Croft
Journal:  Front Immunol       Date:  2012-11-08       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.